EP601 / Epics Therap - LARVOL DELTA

EP601: Agonism of GPR84 activates myeloid cells and augments the response to anti-CTLA4 to promote tumor growth inhibition and prolong survival in a syngeneic (CT26) tumor model (AACR 2025) - "In the CT26 mouse tumor model, CpdA (30 mg/kg, PO, BID) significantly increased the response to anti-CLTA4 (2 mg/kg, IP, BIW) to >80% tumor growth inhibition and improved survival corresponding to altered immune cell infiltration into the tumor. These results demonstrate the potential of pharmacological activation of GPR84 as a novel approach relevant to cancer immunotherapy.1Li et al., Cancer Immunol Immunother (2024)"

IO biomarker • Preclinical • Oncology • IFNG • TNFA